RECRUITING

Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Phase 1/1b, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects. Patients with high risk of peripheral primary lung cancer, stage 1A1/1A2, for whom surgical treatment is planned, will be recruited. Surgery will be performed at 5-21 days following the VTP procedure. Study intervention: robotic assisted bronchoscopic Padeliporfin VTP lung ablation: vascular targeted photodynamic therapy using Padeliporfin photosensitizer.

Official Title

A Multicenter Open-label Phase 1/1b Study to Evaluate Safety, Feasibility and Early Treatment Effect of Padeliporfin VTP Using Robotic Assisted Bronchoscopy and Cone Beam CT Guidance in Patients With Peripheral Lung Cancer

Quick Facts

Study Start:2024-12-28

Study Completion:2028-12-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05918783

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Age ≥18 2. Patients with primary lung lesions who are at high risk for primary lung cancer. 2.1.Biopsy with intraoperative confirmation of malignancy using on-site cytology will be used as final inclusion prior to study treatment. 3. All patients will be approved by a multi-disciplinary team (thoracic surgery, interventional pulmonology, medical oncology and radiation oncology) as appropriate for bronchoscopic VTP prior to surgical resection. 4. Tumor size targeted for VTP treatment ≤ 2 cm (Part A) and \<3cm (Part B), based on CT scan, including solid or semi-solid tumors. 5. EBUS mediastinal staging performed intraoperative prior to VTP treatment with rapid on-site evaluation negative for nodal involvement of malignancy. 6. Tumor is ≥ 2cm from the central bronchial tree (distal 2 cm of the trachea, carina, and named major lobar bronchi up to their first bifurcation) (Timmerman, 2018). 7. Lung lesion is not contiguous with and ≥ 1 cm from the pleura/fissures. 8. Patient is eligible to undergo bronchoscopy under general anesthesia. 9. Tumor is accessible for Padeliporfin VTP treatment via robotic bronchoscopy 10. ECOG performance score 0-2 11. Estimated life expectancy of ≥3 months 12. Adequate organ system function 13. Negative serum pregnancy test	1. Patient has a centrally located lung lesion, as defined by RTOG within 2 cm of the proximal bronchial tree, or within 2 cm of other major mediastinal structure (aorta, heart, trachea, pericardium, superior vena cava, pulmonary artery, esophagus, vertebra's body or spinal canal). 2. Patient has a lung lesion located less than 1 cm from the pleura or fissure 3. Patient has a lung cancer lesion \>2cm in diameter, for the expansion cohort lesion \>2-3 cm 4. Patient has cytologic or histologic evidence of nodal disease 5. Tumor invades major vessels 6. Prior exposure to VTP or PDT treatments 7. Pregnant or breastfeeding women 8. Receiving any other investigational treatment 9. Co-morbidities: 1. Baseline hypoxia with O2 saturation \<92% on 2L NC or more of oxygen 2. New York Heart Association (NYHA) stage III/IV heart failure 3. Unstable coronary artery disease or MI within the last 6 months 4. Uncontrollable clinically serious arrhythmia 5. Decompensated/clinically worsening interstitial lung disease or obstructive lung disease. 6. Unstable cerebrovascular or peripheral vascular disease 7. Inability to stop anticoagulation or anti-platelet therapy peri-procedure 8. Evidence of clinically active infection requiring systemic (any route) antibiotic therapy. All prior infections must have resolved following optimal therapy. 9. Patient has any acute or chronic condition assessed as clinically significant by Investigator which may preclude bronchoscopy procedure 10. History of medical or psychiatric disease which, in the view of the investigator, would preclude safe treatment or acceptable study compliance 11. Known severe pulmonary hypertension (mean pulmonary arterial pressure ≥ 50 mmHg) 10. Patient has a cancer diagnosis with active disease requiring further cancer therapy. 11. Patient has had major surgery within the last 4 weeks. 12. Patient has porphyria or hypersensitivity to padeliporfin or porphyrin-like compounds or to any of its excipients.

Inclusion Criteria

Exclusion Criteria

1. Age ≥18
2. Patients with primary lung lesions who are at high risk for primary lung cancer.
2.1.Biopsy with intraoperative confirmation of malignancy using on-site cytology will be used as final inclusion prior to study treatment.
3. All patients will be approved by a multi-disciplinary team (thoracic surgery, interventional pulmonology, medical oncology and radiation oncology) as appropriate for bronchoscopic VTP prior to surgical resection.
4. Tumor size targeted for VTP treatment ≤ 2 cm (Part A) and \<3cm (Part B), based on CT scan, including solid or semi-solid tumors.
5. EBUS mediastinal staging performed intraoperative prior to VTP treatment with rapid on-site evaluation negative for nodal involvement of malignancy.
6. Tumor is ≥ 2cm from the central bronchial tree (distal 2 cm of the trachea, carina, and named major lobar bronchi up to their first bifurcation) (Timmerman, 2018).
7. Lung lesion is not contiguous with and ≥ 1 cm from the pleura/fissures.
8. Patient is eligible to undergo bronchoscopy under general anesthesia.
9. Tumor is accessible for Padeliporfin VTP treatment via robotic bronchoscopy
10. ECOG performance score 0-2
11. Estimated life expectancy of ≥3 months
12. Adequate organ system function
13. Negative serum pregnancy test

1. Patient has a centrally located lung lesion, as defined by RTOG within 2 cm of the proximal bronchial tree, or within 2 cm of other major mediastinal structure (aorta, heart, trachea, pericardium, superior vena cava, pulmonary artery, esophagus, vertebra's body or spinal canal).
2. Patient has a lung lesion located less than 1 cm from the pleura or fissure
3. Patient has a lung cancer lesion \>2cm in diameter, for the expansion cohort lesion \>2-3 cm
4. Patient has cytologic or histologic evidence of nodal disease
5. Tumor invades major vessels
6. Prior exposure to VTP or PDT treatments
7. Pregnant or breastfeeding women
8. Receiving any other investigational treatment
9. Co-morbidities:
1. Baseline hypoxia with O2 saturation \<92% on 2L NC or more of oxygen
2. New York Heart Association (NYHA) stage III/IV heart failure
3. Unstable coronary artery disease or MI within the last 6 months
4. Uncontrollable clinically serious arrhythmia
5. Decompensated/clinically worsening interstitial lung disease or obstructive lung disease.
6. Unstable cerebrovascular or peripheral vascular disease
7. Inability to stop anticoagulation or anti-platelet therapy peri-procedure
8. Evidence of clinically active infection requiring systemic (any route) antibiotic therapy. All prior infections must have resolved following optimal therapy.
9. Patient has any acute or chronic condition assessed as clinically significant by Investigator which may preclude bronchoscopy procedure
10. History of medical or psychiatric disease which, in the view of the investigator, would preclude safe treatment or acceptable study compliance
11. Known severe pulmonary hypertension (mean pulmonary arterial pressure ≥ 50 mmHg)
10. Patient has a cancer diagnosis with active disease requiring further cancer therapy.
11. Patient has had major surgery within the last 4 weeks.
12. Patient has porphyria or hypersensitivity to padeliporfin or porphyrin-like compounds or to any of its excipients.

Contacts and Locations

Study Contact

Eyal Morag, MD

CONTACT

+972542056619

eyal.morag@impactbiotech.com

Principal Investigator

Lonny Yarmus, MD

PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Study Locations (Sites)

Johns Hopkins University School of Medicine

Baltimore, Maryland, 21224

United States

Collaborators and Investigators

Sponsor: Impact Biotech Ltd

Lonny Yarmus, MD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-12-28

Study Completion Date2028-12-30

Study Record Updates

Study Start Date2024-12-28

Study Completion Date2028-12-30

Terms related to this study

Additional Relevant MeSH Terms

Peripheral Lung Tumor